Document is current
Any future updates will be listed below
-
Authors
Yang, Minglei https://orcid.org/0000-0001-9957-7608
Zheng, Chenxi
Miao, Yu
Yin, Cuicui
Tang, Longfei
Zhang, Chongli
Yu, Pu
Han, Qingfang
Ma, Yihui
Li, Shenglei
Jiang, Guozhong
Li, Wencai
Xia, Peiyi
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04137900 at ClinicalTrials.govDocuments that mention this clinical trial
<i>BTLA</i> promoter hypomethylation correlates with enhanced immune cell infiltration, favorable prognosis, and immunotherapy response in melanoma
https://doi.org/10.1136/jitc-2024-009841
Phase I dose-escalation and cohort expansion study of the anti-BTLA antibody, tifcemalimab, in combination with toripalimab (anti-PD-1) in heavily pretreated patients (pts) with advanced malignancies.
https://doi.org/10.1200/jco.2024.42.16_suppl.2596
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (NO. 82302961)
Henan Province medical science and technology research project (LHGJ20230285)
the Youth Innovation Fund of The First Affiliated Hospital of Zhengzhou University (NO. 71261)
- License Information
